跳至主要内容
临床试验/NL-OMON45504
NL-OMON45504已完成4 期

Bioequivalence study of CRUshed Sofosbuvir/velpAtasvir compareD to the wholE tablet (CRUSADE-1)/Hep-NED004 - CRUSADE-1

Afdeling Apotheek0 个研究点目标入组 11 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
11

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • 1.Patients with sofosbuvir/velpatasvir treatment for the treatment of chronic hepatitis C genotype 1 through 6.
  • 2. Patient is at least 18 at the day of screening.
  • 3. Patient is able and willing to sign the Informed Consent Form.
  • 4. Patient is able and willing to follow protocol requirements.

排除标准

  • 1. Pregnant female (as confirmed by an hCG test performed 4 weeks before Day 84) or breast-feeding female.
  • 2. Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion except for conditions related to HCV.
  • 3. Inability to understand the nature and extent of the study and the procedures required.
  • 4. Clinically relevant low hemoglobin concentration at screening judged by the patient*s own physician.

研究者

发起方
Afdeling Apotheek

相似试验